A new study has found that a high proportion of MS patients with no evidence of disease activity (NEDA) in the first two years of treatment will experience relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) (Prosperini et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059). Read More
Latest News
ECTRIMS 2021 HIGHLIGHTS – FRIDAY, OCTOBER 15 EDITION
October 15, 202137th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 13-15, 2021
The following summarizes some of the highlights from Day 3 of ECTRIMS 2021.
ECTRIMS 2021 POSTER PICKS – DAY 3
October 15, 202137th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 13-15, 2021 Read More
ECTRIMS 2021 HIGHLIGHTS – THURSDAY, OCTOBER 14 EDITION
October 14, 202137th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 13-15, 2021
The following summarizes some of the highlights from Day 2 of ECTRIMS 2021.